Current advances in biomarkers for targeted therapy in triple-negative breast cancer

Current advances in biomarkers for targeted therapy in triple-negative breast cancer

Abstract: Triple-negative breast cancer (TNBC) is a complex heterogeneous disease characterized by the absence of three hallmark receptors: human epidermal growth factor receptor 2, estrogen receptor, and progesterone receptor. Compared to other breast cancer subtypes, TNBC is more aggressive, has a...

Descripció completa

Guardat en:

Dades bibliogràfiques
Autors principals:	Brett Fleisher, Charlotte H. Clarke, Sihem Ait‐Oudhia
Format:	Revisão
Idioma:	anglès
Publicat:	2016
Accés en línia:	https://doi.org/10.2147/bctt.s114659 https://www.dovepress.com/getfile.php?fileID=32807
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

Current advances in biomarkers for targeted therapy in triple-negative breast cancer
per: Fleisher, Brett, et al.
Publicat: (2016)

In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach
per: Fleisher, Brett, et al.
Publicat: (2021)

A retrospective examination of the US Food and Drug Administration’s clinical pharmacology reviews of oncology biologics for potential use of therapeutic drug monitoring
per: Fleisher, Brett, et al.
Publicat: (2017)

Chloroquine sensitizes MDA-MB-231 cells to osimertinib through autophagy–apoptosis crosstalk pathway
per: Fleisher, Brett, et al.
Publicat: (2019)

Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches
per: Kamta, Jeff, et al.
Publicat: (2017)

Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches
per: Jeff Kamta, et al.
Publicat: (2017)

Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
per: Franco, Yesenia L, et al.
Publicat: (2018)

Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
per: Yesenia L. Franco, et al.
Publicat: (2018)

Utility of a Novel Three-Dimensional and Dynamic (3DD) Cell Culture System for PK/PD Studies: Evaluation of a Triple Combination Therapy at Overcoming Anti-HER2 Treatment Resistance in Breast Cancer
per: Ande, Anusha, et al.
Publicat: (2018)

Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy
per: Robainas, Marianela, et al.
Publicat: (2017)

Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy
per: Marianela Robainas, et al.
Publicat: (2017)

Current Issues of Targeted Therapy in Metastatic Triple-Negative Breast Cancer
per: Liedtke, Cornelia, et al.
Publicat: (2011)

Current Photoactive Molecules for Targeted Therapy of Triple-Negative Breast Cancer
per: Dias, Cristina J., et al.
Publicat: (2021)

Targeted Therapies in Triple-Negative Breast Cancer
per: Marmé, Frederik, et al.
Publicat: (2015)

Targeted Therapies in Triple-Negative Breast Cancer
per: Frederik Marmé, et al.
Publicat: (2015)

Advances in systemic therapies for triple negative breast cancer
per: Roberto A. Leon‐Ferre, et al.
Publicat: (2023)

Triple-negative breast cancer: promising prognostic biomarkers currently in development
per: Sukumar, Jasmine, et al.
Publicat: (2021)

Triple-negative breast cancer: promising prognostic biomarkers currently in development
per: Jasmine Sukumar, et al.
Publicat: (2020)

Erythropoietin induced erythroid precursor pool depletion causes erythropoietin hyporesponsiveness
per: Yan, Xiaoyu, et al.
Publicat: (2012)

Mechanisms, monitoring, and management of tyrosine kinase inhibitors–associated cardiovascular toxicities
per: Chaar, Maher, et al.
Publicat: (2018)

Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities
per: Maher Chaar, et al.
Publicat: (2018)

Recent advances in targeted strategies for triple-negative breast cancer
per: Shuangli Zhu, et al.
Publicat: (2023)

Novel therapy for locally advanced triple-negative breast cancer
per: YAMADA, ATSUKO, et al.
Publicat: (2015)

Simultaneous Pharmacokinetics/Pharmacodynamics Modeling of Recombinant Human Erythropoietin upon Multiple Intravenous Dosing in Rats
per: Ait-Oudhia, Sihem, et al.
Publicat: (2010)

In vitro to clinical translational pharmacokinetic/pharmacodynamic modeling of doxorubicin (DOX) and dexrazoxane (DEX) interactions: Safety assessment and optimization
per: Hardik Mody, et al.
Publicat: (2023)

Triple-negative breast cancer and the potential for targeted therapy
per: Jhan, Jing-Ru, et al.
Publicat: (2017)

Triple-Negative Breast Cancer and the Potential for Targeted Therapy
per: Jing-Ru Jhan, et al.
Publicat: (2017)

Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications
per: Karama Asleh, et al.
Publicat: (2022)

Targeting the androgen receptor in triple-negative breast cancer: current perspectives
per: Mina, Alain, et al.
Publicat: (2017)

Targeting the androgen receptor in triple-negative breast cancer: current perspectives
per: Alain Mina, et al.
Publicat: (2017)

RNA-Based Therapeutics: Current Developments in Targeted Molecular Therapy of Triple-Negative Breast Cancer
per: Haque, Sakib, et al.
Publicat: (2021)

A review of current progress in triple-negative breast cancer therapy
per: Shen, Meiying, et al.
Publicat: (2020)

Triple-negative breast cancer therapy: Current and future perspectives (Review)
per: Won, Kwang-Ai, et al.
Publicat: (2020)

Triple‑negative breast cancer therapy: Current and future perspectives (Review)
per: Kwang‐Ai Won, et al.
Publicat: (2020)

A review of current progress in triple-negative breast cancer therapy
per: Meiying Shen, et al.
Publicat: (2020)

Systems Pharmacological Analysis of Paclitaxel-Mediated Tumor Priming That Enhances Nanocarrier Deposition and Efficacy
per: Ait-Oudhia, Sihem, et al.
Publicat: (2013)

Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology
per: Ait-Oudhia, Sihem, et al.
Publicat: (2014)

Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity
per: Ait-Oudhia, Sihem, et al.
Publicat: (2016)

Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer
per: Shi, Jinhong, et al.
Publicat: (2020)

Advances in immunotherapy for triple-negative breast cancer
per: Yang Liu, et al.
Publicat: (2023)